© Schattauer 2016. Increased plasma levels of von Willebrand factor antigen (vWF:Ag) are associated with high risk of coronary artery disease. The effect of statin therapy on vWF:Ag levels remains uncertain. Therefore the aim of this meta-analysis was to evaluate the effect of statin therapy on vWF:Ag Levels. A systematic multiple-database search was carried out to identify randomized controlled trials (RCTs) that investigated the effect of statins on plasma vWF:Ag levels. Random-effect meta-analy-sis of 21 treatment arms revealed a significant decrease in plasma vWF:Ag levels following statin therapy (SMD: -0.54, 95 %CI: -0.87, -0.21, p=0.001). In subgroup analyses, the greatest effect was observed with simvastatin (SMD: -1.54, 95 %>CI: -2.92, -0.17, p=0.028) and pravastatin (SMD: -0.61, 95 %>CI: -1.18, -0.04, p=0.035), but not with fluvastatin (SMD: -0.34, 95 %>CI: -0.69, 0.02, p=0.065), atorvas-tatin (SMD: -0.23, 95 %>CI: -0.57, 0.11, p=0.179) and rosuvastatin (SMD: -0.20, 95 %% CI: -0.71, 0.30, p=0.431). The lowering effect of statins on plasma vWF:Ag levels was greater in the subset of studies lasting > 12 weeks (SMD: -0.70, 95 %>CI: -1.19, -0.22, p=0.005) compared with that of studies lasting <12 weeks (SMD: -0.34, 95 %>CI: -0.67, 0.003, p=0.052). Finally, low-intensity statin therapy was not associated with a significant reduction in vWF:Ag levels (SMD: -0.28, 95%CI: -0.82, 0.27, p=0.320), but a significant effect was observed in high-intensity statin trials (SMD: -0.66, 95 %>CI: -1.07, -0.24, p=0.002). This meta-analysis of available RCTs demonstrates a significant reduction in plasma vWF:Ag levels following statin therapy.
Sahebkar, A., Serban, C., Ursoniu, S., Mikhailidis, D. P., Undas, A., Lip, G. Y. H., ... Banach, M. (2016). The impact of statin therapy on plasma levels of von Willebrand factor antigen: Systematic review and meta-analysis of Randomised placebo-controlled trials. Thrombosis and Haemostasis, 115(3), 520-532. https://doi.org/10.1160/TH15-08-0620